Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) reported positive results from AEGIS, an open-label registration study examining Soliris(R) (eculizumab) treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH). The pre-specified primary efficacy endpoint of change in hemolysis was achieved with an 86 percent reduction (P
— Hemolysis, the primary trial endpoint, was rapidly and significantly
reduced with Soliris treatment. A standard measure of hemolysis,
lactate dehydrogenase (LDH), decreased 86 percent from a median of
1,814 U/L at baseline to a median of 244 U/L following 12 weeks of
treatment (P